Philippines: Deadline Nears For Disclosing Financial Links To Health Care Professionals
New disclosure guidelines in the Philippines subject companies to additional compliance obligations and greater transparency in their dealings with health care providers and professionals.
You may also be interested in...
Vutrisiran, Alnylam’s investigational RNAi therapeutic for treating hereditary transthyretin-mediated amyloidosis in adults with polyneuropathy, is among the latest new medicines that have been submitted for review for potential pan-EU approval.
Two companies are set to learn whether the European Medicines Agency will agree that their planned EU marketing applications merit an accelerated assessment.
Patients in England with non-small cell lung cancer will be the first In Europe to be offered Amgen’s KRAS G12C inhibitor.